National Epidemiological Case–Control Study of Pharmacological Smoking Cessation Treatment in Danish Patients with Chronic Obstructive Pulmonary Disease

National Epidemiological Case–Control Study of Pharmacological Smoking Cessation Treatment in Danish Patients with Chronic Obstructive Pulmonary Disease

Dea Kejlberg Andelius,1 Ole Hilberg,2,3 Rikke Ibsen,4 Anders Løkke2,3 1Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark; 2Department of Medicine, Vejle, Little Belt Hospital, Vejle, Denmark; 3Department of Regional Health Research, University of Southern...

Full description

Bibliographic Details
Main Authors:	Andelius DK, Hilberg O, Ibsen R, Løkke A
Format:	Article
Language:	English
Published:	Dove Medical Press 2021-08-01
Series:	International Journal of COPD
Subjects:	nicotine bupropion varenicline smoking cessation copd
Online Access:	https://www.dovepress.com/national-epidemiological-casecontrol-study-of-pharmacological-smoking--peer-reviewed-fulltext-article-COPD

Similar Items

Evaluation of pharmacologic therapies accompanied by behavioural therapy on smoking cessation success: a prospective cohort study in Turkey
by: Kamile Marakoğlu, et al.
Published: (2017-07-01)

A comparison of the efficacy of varenicline and bupropion and an evaluation of the effect of the medications in the context of the smoking cessation programme
by: Ali Ramazan Benli, et al.
Published: (2017-02-01)

Review: Pharmacotherapy for smoking cessation
by: Chok Limsuwat, et al.
Published: (2018-07-01)

An integrated approach to pharmacotherapy in smoking cessation: the role of varenicline, bupropion, cytisine, and nicotine replacement therapy
by: Kacper Więcław, et al.
Published: (2023-08-01)

Does Smoking Affect OSA? What about Smoking Cessation?
by: Athanasia Pataka, et al.
Published: (2022-08-01)

Tobacco smoking cessation management: integrating varenicline in current practice
by: Laurence M Galanti
Published: (2008-08-01)

Comparative assessment of outcomes of smoking cessation therapies and role of free medications in successful long-term abstinence
by: Bengu Saylan, et al.
Published: (2021-06-01)

Cost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessation
by: Lieven Annemans, et al.
Published: (2015-01-01)

Smoking cessation and COPD
by: Philip Tønnesen
Published: (2013-03-01)

Medication-assisted quit rates in participants with smoking-related diseases in EAGLES: Post hoc analyses of a double-blind, randomized, placebo-controlled clinical trial
by: Philip Tønnesen, et al.
Published: (2022-05-01)

Real world evaluation of three models of NHS smoking cessation service in England
by: Mardle Tony, et al.
Published: (2012-01-01)

Pharmacotherapy in Effort to Quit Smoking
by: Diyan Ekawati, et al.
Published: (2016-05-01)

Combination of behavioral therapy and varenicline for smoking cessation: Time to beat nicotine
by: Avnica Agarwal, et al.
Published: (2022-01-01)

Smoking cessation in severe mental ill health: what works? an updated systematic review and meta-analysis
by: Emily Peckham, et al.
Published: (2017-07-01)

Youth tobacco use cessation: 2008 update
by: Steve Sussman, et al.
Published: (2009-01-01)

Evaluation of the nicotine metabolite ratio in smoking patients treated with varenicline and bupropion
by: Paulo Roberto Xavier Tomaz, et al.
Published: (2022-07-01)

Efficacy and Safety of Varenicline for Smoking Cessation in Schizophrenia: A Meta-Analysis
by: Saeed Ahmed, et al.
Published: (2018-09-01)

Smoking cessation in diabetic patients
by: Paraskevi Katsaounou, et al.
Published: (2019-10-01)

Socioeconomic inequality in the use of prescription medications for smoking cessation among patients with COPD: a nationwide study
by: Tøttenborg SS, et al.
Published: (2018-05-01)

Pharmacological Treatment for Pregnant Women who Smoke Cigarettes
by: BC Chan, et al.
Published: (2003-09-01)

Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals
by: Edward J Mills, et al.
Published: (2010-07-01)

Pharmacological Basis of the Clinical Efficacy of Varenicline Used to Facilitate Smoking Cessation
by: S. R. Gilyarevskiy
Published: (2019-03-01)

Varenicline in smokers with severe or very severe COPD after 24 weeks of treatment. A descriptive analysis: VALUE study
by: Carlos A. Jiménez-Ruiz, et al.
Published: (2017-12-01)

Varenicline and evaluated outcomes in smoking cessation programmes
by: P. Santus, et al.
Published: (2015-11-01)

Using cost-effectiveness analysis to support policy change: varenicline and nicotine replacement therapy for smoking cessation in Jordan
by: Saba Madae’en, et al.
Published: (2020-12-01)

TOB-STOP-COP (TOBacco STOP in COPd trial): study protocol—a randomized open-label, superiority, multicenter, two-arm intervention study of the effect of “high-intensity” vs. “low-intensity” smoking cessation intervention in active smokers with chronic obstructive pulmonary disease
by: Mohamad Isam Saeed, et al.
Published: (2020-08-01)

Varenicline treatment for smoking cessation in high risk patients: a budget impact analysis
by: Federico Spandonaro, et al.
Published: (2017-10-01)

A cost-effectiveness analysis of varenicline for smoking cessation using data from the EAGLES trial
by: Baker CL, et al.
Published: (2018-01-01)

Varenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherence
by: Burke MV, et al.
Published: (2016-04-01)

The tobacco epidemic – pharmacological interventions for smoking cessation
by: Natalia Sergiel, et al.
Published: (2023-08-01)

Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis
by: Kyla H Thomas, et al.
Published: (2021-10-01)

Varenicline versus nicotine replacement therapy for long-term smoking cessation: an observational study using the Clinical Practice Research Datalink
by: Neil M Davies, et al.
Published: (2020-02-01)

SMOKING AS A RISK FACTOR FOR CARDIOVASCULAR AND CEREBROVASCULAR DISEASES: PREVALENCE, IMPACT ON PROGNOSIS, POSSIBLE SMOKING CESSATION STRATEGIES AND THEIR EFFECTIVENESS. Part 2. Advantages of quitting smoking. Strategies to quit smoking
by: O. D. Ostroumova, et al.
Published: (2018-03-01)

Tobacco cessation pharmacotherapy use among racial/ethnic minorities in the United States: Considerations for primary care
by: Monica Webb Hooper, et al.
Published: (2017-10-01)

A Single-Case Experimental Design to Study the Combination of Cognitive-Behavioral Therapy and Pharmacotherapy for Smoking Cessation
by: Bijan Pirnia, et al.
Published: (2019-01-01)

Nicotine addiction and smoking cessation strategies
by: Michael Kourakos, et al.
Published: (2016-03-01)

Menthol cigarettes and smoking cessation behavior
by: Allison C. Hoffman, et al.
Published: (2011-05-01)

ABC of smoking cessation /
by: Britton, John
Published: (2004)

Efficacy of nicotine-replacement therapy, bupropion, and a combination of both for treating nicotine addiction: a randomized clinical trial
by: Dalia A Abdelghany, et al.
Published: (2022-01-01)

Naltrexone and Bupropion Combination Treatment for Smoking Cessation and Weight Loss in Patients With Schizophrenia
by: Xuechan Lyu, et al.
Published: (2018-03-01)